Abstract
Non-alcoholic fatty liver disease (NAFLD) is a clinico-pathologic spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Although simple or bland steatosis follows a relatively benign clinical course, NASH can potentially progress to cirrhosis (approximately 10 to 15 percent) and hepatocellular carcinoma. NAFLD occurs in an estimated 25 to 30 percent of the US general population, while NASH is reported in 2 to 3 percent of the population. Even though common explanation for the increased prevalence of NAFLD is the increased rate of obesity, the risk of developing NAFLD and NASH is not limited to overweight and obese individuals. Currently, the only way to diagnose NASH or to assess the stage of fibrosis is by obtaining a liver biopsy. Liver biopsy is invasive, expensive, and associated with potential risks, including post biopsy pain, bleeding, organ perforation, and even death; serious complications can occur in 0.3 percent of liver biopsies with 0.01 percent being fatal. This review examines the current strategies for development of the non-invasive techniques that will one day replace liver biopsy and serve as a non-invasive gold standard for the diagnosis and staging of NASH.
Keywords: Obesity, non-alcoholic fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis, Bax
Current Molecular Medicine
Title: Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease
Volume: 10 Issue: 2
Author(s): J. M. Estep, A. Birerdinc and Z. Younossi
Affiliation:
Keywords: Obesity, non-alcoholic fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis, Bax
Abstract: Non-alcoholic fatty liver disease (NAFLD) is a clinico-pathologic spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Although simple or bland steatosis follows a relatively benign clinical course, NASH can potentially progress to cirrhosis (approximately 10 to 15 percent) and hepatocellular carcinoma. NAFLD occurs in an estimated 25 to 30 percent of the US general population, while NASH is reported in 2 to 3 percent of the population. Even though common explanation for the increased prevalence of NAFLD is the increased rate of obesity, the risk of developing NAFLD and NASH is not limited to overweight and obese individuals. Currently, the only way to diagnose NASH or to assess the stage of fibrosis is by obtaining a liver biopsy. Liver biopsy is invasive, expensive, and associated with potential risks, including post biopsy pain, bleeding, organ perforation, and even death; serious complications can occur in 0.3 percent of liver biopsies with 0.01 percent being fatal. This review examines the current strategies for development of the non-invasive techniques that will one day replace liver biopsy and serve as a non-invasive gold standard for the diagnosis and staging of NASH.
Export Options
About this article
Cite this article as:
Estep M. J., Birerdinc A. and Younossi Z., Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease, Current Molecular Medicine 2010; 10 (2) . https://dx.doi.org/10.2174/156652410790963321
DOI https://dx.doi.org/10.2174/156652410790963321 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
De Novo Design of High Potent DPP-IV Inhibitors Based on the Scaffold of Cyanopyrrolidine
Letters in Drug Design & Discovery Cyclophilin A: A Predictive Biomarker of Carotid Stenosis in Cerebral Ischemic Stroke
Current Neurovascular Research Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A New Short Validated U-HPLC Method for the Determination of Recombinant Human Insulin in Microspheres
Current Pharmaceutical Analysis Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Editorial Review (Thematic Issue: An Update on Central Sensitivity Syndromes and the Issues of Nosology and Psychobiology)
Current Rheumatology Reviews Looking for New Inhibitors for the Epidermal Growth Factor Receptor
Current Topics in Medicinal Chemistry Editorial
Current Molecular Imaging (Discontinued) Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture A Brief Survey for MicroRNA Precursor Identification Using Machine Learning Methods
Current Genomics Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Mesenchymal Stem Cell-derived Extracellular Vesicles for Renal Repair
Current Gene Therapy FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design